Tesamorelin Research

Falutz J, Mamputu JC, Potvin D, et al.

The pivotal Phase 3 trial data that led to tesamorelin’s FDA approval. The pooled analysis of 806 HIV-infected patients with lipodystrophy showed that daily tesamorelin 2mg reduced visceral adipose tissue (VAT) by 17.5% at 26 weeks — and maintained that reduction at 52 weeks with continued treatment. Waist circumference decreased 3.4 cm, triglycerides dropped significantly, and body image improved. IGF-1 increased by a mean of 108 ng/ml. Critically, glucose parameters remained stable — addressing a key concern about GH axis stimulation in patients with metabolic complications. This paper established tesamorelin as the evidence standard for GHRH-based visceral fat reduction.

Ishida J, Saitoh M, Ebner N, et al.

A comprehensive review covering tesamorelin’s development and approval in the context of the broader GH secretagogue class. The paper explains how tesamorelin’s N-terminal modification (trans-3-hexenoyl group) protects it from DPP-4 enzyme degradation — giving it a longer half-life than native GHRH or sermorelin. It also covers tesamorelin’s favorable Phase 2 and 3 clinical data showing reduced trunk and visceral fat, increased lean body mass, decreased waist circumference, and improvements in triglycerides and cholesterol. A key reference for understanding how tesamorelin differs from other GHRH analogs at the molecular and clinical level.

Friedman SD, Baker LD, Borson S, et al.

A 20-week randomized trial in which healthy older adults and adults with mild cognitive impairment self-administered daily tesamorelin. The study found that tesamorelin altered brain neurochemical levels — specifically GABA, an inhibitory neurotransmitter — and documented cognitive improvements. The research team’s prior trial with sermorelin had shown improvements in working memory, planning, and selective attention; this trial extended those findings using tesamorelin and MRI brain spectroscopy to measure actual neurochemical changes, providing a plausible biological mechanism for GH secretagogues’ cognitive effects.

ScienceDirect / Pharmacological Research

Clinical trial evidence showing that tesamorelin reduced liver fat content and prevented liver inflammation and fibrosis progression in HIV patients with non-alcoholic fatty liver disease (NAFLD). This extended tesamorelin’s clinical relevance beyond visceral fat reduction and into liver disease — one of the most common and serious metabolic complications in HIV-treated patients. A prospective Phase II trial in non-HIV NAFLD patients subsequently began (NCT03375788), suggesting tesamorelin’s liver protective effects may have broader applications beyond the HIV-lipodystrophy population.